Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (ANAVEX)

Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period

The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship between dosing regimen and pharmacodynamics efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease
• Intervention / Treatment: Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Intravenous; Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Oral

Detailed Description

This is a Phase 2a study consisting of two parts, PART A and PART B. The first part (PART A) is a simple randomised, open-label, 2-period, cross-over, adaptive design study lasting for each participant up to 36 days.

The second part (PART B) is an open-label extension for an additional period of 52 weeks, so as to establish a longer drug effect for the participants who wish to continue on oral daily dose.

The complete timeline of the study includes the screening assessments within 28 days prior to simple randomisation and initiation of the study. The first administration of study medication will occur after all baseline and screening procedures have been passed (baseline is defined as pre-dosing period timeframe day -28 to day -1). No study procedures will be undertaken until a current informed consent form has been signed by each participant or their respective carer or responsible person.

The design of the first part (PART A) of the study involves two periods, two administration routes and two dose levels: In one period the intravenous (iv) form will be given and in the other period the oral dose will be given. The first period will involve 12 administrations (either oral or iv) and the second period will involve 11 administrations (either oral or iv).

The very first administration in the first period is intended as a full pharmacokinetic (PK) screen over the first 48 hours (Day 1 to Day 3). After that, 11 daily administrations complete the first period (Day 3 to Day 13). After a wash-out period of 11 days, the second period of the study starts, involving again 11 daily administrations. Therefore, the first part (PART A) of the study is scheduled to be completed in 36 days.

The study design asks for 32 participants, 16 males and 16 female participants. All participants have the option to go on to the second part (PART B) of the study, the extended open-label study exploring the cognitive effect of the drug for another 52 weeks where the oral form will be exclusively administered.

Safety and tolerability will be constantly assessed throughout the study, starting from the first dose of study medication.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3050
      • Melbourne Health - The Royal Melbourne Hospital
    • Melbourne, Victoria, Australia, 3084
      • Austin Health - Heidelberg Repatriation Hospital
    • Melbourne, Victoria, Australia, 3162
      • Caulfield Hospital
    • Melbourne, Victoria, Australia
      • Nucleus Network- Centre for Clinical Studies
    • Melbourne, Victoria, Australia
      • St. Vincent's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Main Inclusion Criteria:

1. Diagnosis of Probable AD in accordance with NINCDS-ADRDA criteria.
2. A brain CT or MRI scan performed within last 12 months from day of screening consistent with the clinical diagnosis of probable AD.
3. Age from 55 to 85 years inclusive.
4. MMSE score of 16-28 inclusive.
5. Rosen Modified Hachinski Ischemic score <=4.
6. Community dwelling with caregiver who has regular contact with the subject for at least 10 hours per week and is able to oversee the patient's compliance with study medication and participate in the patient's clinical assessment and is capable of accompanying the participant on all clinic visits.
7. Fluency in English.
8. Be able to read, write, speak clearly for the cognitive tests, with eyesight and hearing sufficient to enable completion of the cognitive tests.
9. Receiving stable doses of medications for the treatment of non-excluded medical conditions for at least 30 days prior to screening.

Main Exclusion Criteria:

1. Dementia other than AD such as AIDS, CJD, LBD, CVD, Progressive Supranuclear Palsy, Multiple cerebral infarcts, or normal pressure hydrocephalus.
2. Other neurodegenerative diseases, including Parkinson's disease and Huntington's disease, or cerebral tumour.
3. Current presence of a clinically significant major psychiatric disorder according to the criteria of the DSM-IV, or symptom that could affect the participant's ability to complete the study). HAM-D score >12.
4. Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
5. Any other criteria which in the opinion of the Investigator causes the participant not to qualify for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Anavex2-73 oral then the Anavex2-73 intravenous formulation; Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.	Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Intravenous; Drug: ANAVEX2-73 Oral; 30 mg hard gelatin capsule; Drug: ANAVEX2-73 Oral; 50 mg hard gelatin capsule
Experimental: Anavex2-73 intravenous then the Anavex2-73 oral formulation; Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.	Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Intravenous; Drug: ANAVEX2-73 Oral; 30 mg hard gelatin capsule; Drug: ANAVEX2-73 Oral; 50 mg hard gelatin capsule
Experimental: Anavex2-73 30 mg oral formulation; Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.	Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Oral; 30 mg hard gelatin capsule; Drug: ANAVEX2-73 Oral; 50 mg hard gelatin capsule
Experimental: Anavex2-73 50 mg oral formulation; Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.	Drug: ANAVEX2-73 Oral; Drug: ANAVEX2-73 Oral; 30 mg hard gelatin capsule; Drug: ANAVEX2-73 Oral; 50 mg hard gelatin capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To determine maximum tolerated dose of Anavex2-73.	36 Days

Secondary Outcome Measures

Outcome Measure	Time Frame
PK sampling- blood test results	First part (PART A), first period (hours): 1, 48, 264; second period (hours): 1, 72, 264; extension period (PART B): Week 1, 12 and 26.
Mini-mental state examination score (MMSE)	Baseline, and during the extension period at Week 1, 12, 26, 36, 48, and 52
Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)	Baseline, and during the extension period at Week 1, 12, 26, 36, 48, and 52
Cogstate Brief Battery (CBB) Score and International Shopping List Task (ISLT) Score	At baseline, Day 1, 2, 6, 9, 12 of Period 1 and Day 1, 2, 6, 9, 12 of Period 2 and during the extension period at Week 12, 36, 48, and 52.
Electroencephalographic activity, including event-related potentials (EEG/ERP)	baseline, Day 1, 5, 11 of Period 1 and Day 1, 5, 11 of Period 2 and, Week 12, 36, 48, and 52 of the extension period
Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score	Baseline at Period 1
Rosen Modified Hachinski Ischemic Score (RM/HIS10)	Baseline at period 1

Collaborators and Investigators

• Sponsor: Anavex Life Sciences Corp.
• Investigators: Principal Investigator: Stephen Macfarlane, Caulfield Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2014
• Primary Completion (Actual): November 1, 2015
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: August 31, 2014
• First Submitted That Met QC Criteria: September 17, 2014
• First Posted (Estimate): September 19, 2014

Study Record Updates

• Last Update Posted (Actual): November 28, 2018
• Last Update Submitted That Met QC Criteria: November 26, 2018
• Last Verified: November 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease
• Other Study ID Numbers: ANAVEX2-73-002